Comparative efficacy of cyclandelate versus flunarizine in the prophylactic treatment of migraine.

abstract：:The incidence of infection in clean surgery (i.e. surgery with no major contamination of the operative site) should be less than 2%, although the incidence of postoperative infections can be higher in patients with various risk factors (namely insertion of foreign bodies, a compromised immune status or prolonged durat...

journal_title：Drugs

authors： Mini E,Nobili S,Periti P

更新日期：1997-01-01 00:00:00

abstract：:Patients with oncogene-driven lung cancer have limited therapeutic options after progressing on their targeted tyrosine kinase inhibitor (TKI) therapy. Given the growing role of immune checkpoint inhibitor (ICI) therapy in the treatment of lung cancer, oncogene-driven cancer has warranted further evaluation regarding ...

journal_title：Drugs

authors： Somasundaram A,Socinski MA,Villaruz LC

更新日期：2020-06-01 00:00:00

abstract：:Sulbactam 1g and ampicillin 2g were administered intravenously to 12 patients, and concentrations of the drugs were determined in the serum and myometrium for up to 120 minutes after infusion. The ratio of sulbactam to ampicillin was about 1:2 in the serum and myometrium. Both drugs penetrated well into the myometrium...

journal_title：Drugs

authors： Schwiersch U,Lang N,Wildfeuer DA

更新日期：1986-01-01 00:00:00

abstract：:Conventional formulations of metoprolol have become well established in cardiovascular medicine and are particularly useful in the management of hypertension and ischaemic heart disease. Recently developed controlled release metoprolol delivery systems (metoprolol CR/ZOK and metoprolol OROS) were designed to overcome ...

journal_title：Drugs

authors： Plosker GL,Clissold SP

更新日期：1992-03-01 00:00:00

abstract：:The continuous-use combination oral contraceptive ethinylestradiol/levonorgestrel 20microg/90microg suppresses gonadotropins, and subsequently ovulation and endometrial thickening, and suppresses breakthrough bleeding. Amenorrhoea and absence of breakthrough bleeding increase in incidence with extended administration....

journal_title：Drugs

authors： Wagstaff AJ

更新日期：2007-01-01 00:00:00

abstract：:The increased understanding of the mechanisms which underlie rheumatoid disease has been accompanied by a more appropriate use of the limited repertoire of therapeutic agents. Conventional second-line drugs still have a role in everyday practice. The efficacy of these agents in reducing the severity of clinical signs ...

journal_title：Drugs

authors： Luqmani R,Gordon C,Bacon P

更新日期：1994-02-01 00:00:00

abstract：:We have analysed the published literature on eptacog alfa (recombinant factor VIIa; rFVIIa) for nonhaemophiliac conditions with the aim of determining its current place in therapy. Initial surgical and/or medical management is required for any patient with life-threatening bleeding. In those with continued life-threat...

journal_title：Drugs

authors： Mallarkey G,Brighton T,Thomson A,Kaye K,Seale P,Gazarian M

更新日期：2008-01-01 00:00:00

abstract：:In general, hepatic encephalopathy (HE) is defined as a brain dysfunction caused by liver insufficiency and/or portal-systemic blood shunting. This article relates to the so-called type C HE: that is, HE in patients with liver cirrhosis. It manifests as a wide spectrum of neurological or psychiatric abnormalities, ran...

journal_title：Drugs

authors： Weissenborn K

更新日期：2019-02-01 00:00:00

abstract：:Cytotoxic chemotherapy plays a key role in the treatment of carcinoma for thousands of patients annually who either present with metastatic disease or relapse after surgical excision of apparently localised disease. Unfortunately, there is such a wide range of responsiveness to drug therapy within individual tumour ty...

journal_title：Drugs

authors： Sarosdy MF,Von Hoff DD

更新日期：1983-11-01 00:00:00

abstract：:Olaratumab (Lartruvo™) is a fully human IgG1 monoclonal antibody targeted against the human platelet-derived growth factor (PDGF) receptor α (PDGFRα). It was developed by Eli Lilly and Co. (previously ImClone Systems) after PDGFRα was identified as a potential therapeutic target in a variety of cancers. Olaratumab act...

journal_title：Drugs

authors： Shirley M

更新日期：2017-01-01 00:00:00

abstract：:Alemtuzumab (Lemtrada®) is an anti-CD52 monoclonal antibody approved in the EU for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS). In phase 3 trials in patients with active RRMS, intravenous alemtuzumab was more effective than subcutaneous interferon β-1a in terms of decreasing relapse ra...

journal_title：Drugs

authors： Syed YY

更新日期：2021-01-01 00:00:00

abstract：:Anthracyclines are among the most active drugs for the treatment of advanced breast cancer. Epirubicin has been found to be as effective as doxorubicin at equimolar doses but significantly better tolerated, especially in terms of alopecia, leucopenia, and cardiac toxicity. The role of anthracycline-containing regimens...

journal_title：Drugs

authors： Fumoleau P,Devaux Y,Vo Van ML,Kerbrat P,Fargeot P,Schraub S,Mihura J,Namer M,Mercier M

更新日期：1993-01-01 00:00:00

abstract：:Desloratadine is the orally active major metabolite of the nonsedating H1-antihistamine loratadine. The drug had no adverse cardiovascular effects in various animal models or when administered at 9 times the recommended adult dosage for 10 days in volunteers. Therapeutic dosages had no effects on wakefulness or psycho...

journal_title：Drugs

authors： McClellan K,Jarvis B

更新日期：2001-01-01 00:00:00

abstract：:The clonidine transdermal therapeutic system (TTS) is a cutaneous delivery device which provides therapeutically effective doses of clonidine at a constant rate over 7 days. In clinical trials it reduces blood pressure in patients with mild to moderate hypertension as effectively as oral clonidine but with greater sta...

journal_title：Drugs

authors： Langley MS,Heel RC

更新日期：1988-02-01 00:00:00

abstract：:Page 9, Fig. 2, which originally appeared as. ...

journal_title：Drugs

authors： Mathieson S,Maher CG,Ferreira GE,Hamilton M,Jansen J,McLachlan AJ,Underwood M,Lin CC

更新日期：2020-10-01 00:00:00

abstract：:Viral conjunctivitis is one of the most common disorders observed in ophthalmic emergency departments, yet no established treatment exists. Lately, antiviral medications have been introduced into clinical practice; however, a systematic review focusing on their use and effectiveness in the treatment of viral conjuncti...

journal_title：Drugs

authors： Skevaki CL,Galani IE,Pararas MV,Giannopoulou KP,Tsakris A

更新日期：2011-02-12 00:00:00

abstract：:Torasemide (torsemide) is a high-ceiling loop diuretic which acts on the thick ascending limb of the loop of Henle to promote rapid and marked excretion of water, sodium and chloride. Like furosemide (frusemide), its major site of action is from the luminal side of the cell. Torasemide is at least twice as potent as f...

journal_title：Drugs

authors： Friedel HA,Buckley MM

更新日期：1991-01-01 00:00:00

abstract：:Onychomycoses, infections of the nail caused by fungi, are amongst the most common illnesses. Because of the high incidence of these infections and problems involved in their therapy, they have received much attention, particularly as concerns a better characterisation of the causative micro-organisms. Onychomycosis c...

journal_title：Drugs

authors： Niewerth M,Korting HC

更新日期：1999-08-01 00:00:00

abstract：:Lemborexant (DAYVIGO™) is an orally administered, dual orexin receptor (OXR) antagonist that exhibits reversible competitive antagonism at OXR1 and OXR2 (> affinity at OXR2) that was discovered and developed by Eisai Inc. for the treatment of adult patients with insomnia. In December 2019, lemborexant received its fir...

journal_title：Drugs

authors： Scott LJ

更新日期：2020-03-01 00:00:00

abstract：:Purine nucleoside analogues are a new class of drugs with activity against nondividing lymphocytes; thus, they should play a major role in the treatment of low grade lymphoid malignancies. As these drugs are active against resting lymphocytes, harmful effects related to this action were expected and have been reported...

journal_title：Drugs

authors： Dighiero G

更新日期：1994-01-01 00:00:00

abstract：:This review describes the tolerability profile of nimesulide as documented in a global assessment of the clinical data available to Helsinn for this drug. Data from 151 trials were considered and the relevant case report forms and study reports were used as source information. The analysis was conducted using between-...

journal_title：Drugs

authors： Fusetti G,Magni E,Armandola MC

更新日期：1993-01-01 00:00:00

abstract：UNLABELLED:Fentanyl is a synthetic opioid agonist which interacts primarily with the mu-opioid receptor. The low molecular weight, high potency and lipid solubility of fentanyl make it suitable for delivery by the transdermal therapeutic system. These patches are designed to deliver fentanyl at a constant rate (25, 50,...

journal_title：Drugs

authors： Muijsers RB,Wagstaff AJ

更新日期：2001-01-01 00:00:00

abstract：:The most positive results in this area have been those of the second Danish Study Group on Verapamil in Myocardial Infarction (1990) which assessed the benefit of treatment with verapamil from the second week after myocardial infarction. Verapamil produced a significant reduction in both mortality and reinfarction rat...

journal_title：Drugs

authors： Ferrari R,Visioli O

更新日期：1991-01-01 00:00:00

abstract：:The optimal treatment of pain requires an understanding of the mechanisms involved. Pain is a sensory end-point that can be generated by a number of dissimilar processes. Consequently, the concept of treating pain as a unitary symptom is obsolete. The mechanisms responsible for specific types of pain need to be unders...

journal_title：Drugs

authors： Woolf CJ

更新日期：1994-01-01 00:00:00

abstract：:The successful identification of a range of leukaemia-specific and lymphoma-specific antigens in recent years has stimulated efforts to develop therapeutic vaccination strategies. A number of clinical trials have established the safety and immunogenicity of vaccination against tumour antigens, although there are limit...

journal_title：Drugs

authors： Rezvani K,de Lavallade H

更新日期：2011-09-10 00:00:00

abstract：:Sotagliflozin (Zynquista™) is the first dual inhibitor of sodium-glucose co-transporter-1 and -2 (SGLT1 and 2). In the phase 3, inTANDEM 1-3 trials, adjunctive use of oral sotagliflozin (200 mg or 400 mg once daily) improved glycaemic control and reduced bodyweight and insulin requirements relative to placebo over 24 ...

journal_title：Drugs

authors： Deeks ED

更新日期：2019-12-01 00:00:00

abstract：:Calcitonin is a peptide hormone secreted by the C-cells of the thyroid gland. A major physiological function of the hormone appears to be the protection of the skeleton against resorption in humans. It thus opposes the resorptive actions of parathyroid hormone and 1,25 dihydroxyvitamin D. This action is utilised pharm...

journal_title：Drugs

authors： Stevenson JC,Evans IM

更新日期：1981-04-01 00:00:00

abstract：:Etoposide is one of the most active agents for the therapy of lymphomas. Oral etoposide has proven to be active in and clearly beneficial for patients with previously treated lymphomas. The optimal dose and schedule of oral etoposide for use in combination chemotherapy are still uncertain, but low daily doses (50 to 1...

journal_title：Drugs

authors： Greco FA

更新日期：1999-01-01 00:00:00

abstract：:An acute thrombus at the site of an atherosclerotic obstruction is the usual cause of myocardial infarction. Thrombolytic therapy is an exciting new therapy for reducing the extent of myocardial infarction by lysing intracoronary clots. Such therapy has now been widely applied by: prolonged intravenous infusion of str...

journal_title：Drugs

authors： Spann JF,Sherry S

更新日期：1984-11-01 00:00:00

abstract：:With changing donor characteristics and the growing shortage in organ supply, renal transplant practitioners have sought to optimize the use of expanded criteria donor (ECD) kidneys, which have poorer outcomes than standard criteria donor (SCD) kidneys. The outcomes may represent an acceptable trade-off if ECD transpl...

journal_title：Drugs

authors： House AA,Nguan CY,Luke PP

更新日期：2008-01-01 00:00:00